Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection

Journal of Hepatology

Volumn 63, Issue 5, 2015, Pages 1111-1117

  Yang, Yao Hsu ^a,b,c   Chen, Wen Cheng ^a   Tsan, Yu Tse ^b,d,e   Chen, Mei Jyh ^b,f   Shih, Wei Tai ^a,b   Tsai, Ying Huang ^a,g   Chen, Pau Chung ^b,f  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Cirrhosis; Hepatitis C virus; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK REDUCTION; SEX DIFFERENCE; AGED; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; HEALTH SURVEY; INCIDENCE; MULTICENTER STUDY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TAIWAN;

ADULT; AGED; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAIWAN;

EID: 84945437158     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.07.006     Document Type: Article

References (29)

1. M. Yano, H. Kumada, M. Kage, K. Ikeda, K. Shimamatsu, O. Inoue, and et al. The long-term pathological evolution of chronic hepatitis C Hepatology 23 1996 1334 1340
2. C. Niederau, S. Lange, T. Heintges, A. Erhardt, M. Buschkamp, D. Hurter, and et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study Hepatology 28 1998 1687 1695
3. V. Ng, and S. Saab Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C Clin Gastroenterol Hepatol 9 2011 923 930
4. C. Koh, T. Heller, V. Haynes-Williams, K. Hara, X. Zhao, J.J. Feld, and et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy Aliment Pharmacol Ther 37 2013 887 894
5. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, and et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
6. Y.T. Tsan, C.H. Lee, W.C. Ho, M.H. Lin, J.D. Wang, and P.C. Chen Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection J Clin Oncol 31 2013 1514 1521
7. M.F. Demierre, P.D. Higgins, S.B. Gruber, E. Hawk, and S.M. Lippman Statins and cancer prevention Nat Rev Cancer 5 2005 930 942
8. Y.T. Tsan, C.H. Lee, J.D. Wang, and P.C. Chen Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection J Clin Oncol 30 2012 623 630
9. K. Rombouts, E. Kisanga, K. Hellemans, A. Wielant, D. Schuppan, and A. Geerts Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells J Hepatol 38 2003 564 572
10. T. Miyaki, S. Nojiri, N. Shinkai, A. Kusakabe, K. Matsuura, E. Iio, and et al. Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats Hepatol Res 41 2011 375 385
11. S. Klein, J. Klosel, R. Schierwagen, C. Korner, M. Granzow, S. Huss, and et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats Lab Invest 92 2012 1440 1450
12. J. Trebicka, M. Hennenberg, M. Odenthal, K. Shir, S. Klein, M. Granzow, and et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells J Hepatol 53 2010 702 712
13. T.G. Simon, L.Y. King, H. Zheng, and R.T. Chung Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C J Hepatol 62 2015 18 23
14. M.N. Lai, S.M. Wang, P.C. Chen, Y.Y. Chen, and J.D. Wang Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk J Natl Cancer Inst 102 2010 179 186
15. WHO collaborating center for drugs statistics methodology: ATC/DDD index; 2013. < http://www.whocc.no/atc-ddd-index/ >.
16. S.M. Kieszak, W.D. Flanders, A.S. Kosinski, C.C. Shipp, and H. Karp A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data J Clin Epidemiol 52 1999 137 142
17. A. Denda, T. Endoh, W. Kitayama, Q. Tang, O. Noguchi, Y. Kobayashi, and et al. Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats Carcinogenesis 18 1997 1921 1930
18. H. Yoshiji, S. Kuriyama, and H. Fukui Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor Tumour Biol 23 2002 348 356
19. G. Nkontchou, E. Cosson, M. Aout, A. Mahmoudi, V. Bourcier, I. Charif, and et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients J Clin Endocrinol Metab 96 2011 2601 2608
20. F. Negro Are statins a remedy for all seasons? J Hepatol 62 2015 8 10
21. T. Kisseleva, and D.A. Brenner Anti-fibrogenic strategies and the regression of fibrosis Best Pract Res Clin Gastroenterol 25 2011 305 317
22. M. Eberlein, J. Heusinger-Ribeiro, and M. Goppelt-Struebe Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins) Br J Pharmacol 133 2001 1172 1180
23. V. Paradis, D. Dargere, F. Bonvoust, M. Vidaud, P. Segarini, and P. Bedossa Effects and regulation of connective tissue growth factor on hepatic stellate cells Lab Invest 82 2002 767 774
24. Y. Iwakiri, V. Shah, and D.C. Rockey Vascular pathobiology in chronic liver disease and cirrhosis - Current status and future directions J Hepatol 61 2014 912 924
25. S. SenBanerjee, Z. Lin, G.B. Atkins, D.M. Greif, R.M. Rao, A. Kumar, and et al. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation J Exp Med 199 2004 1305 1315
26. G. Marrone, L. Russo, E. Rosado, D. Hide, G. Garcia-Cardena, J.C. Garcia-Pagan, and et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins J Hepatol 58 2013 98 103
27. S. Sen-Banerjee, S. Mir, Z. Lin, A. Hamik, G.B. Atkins, H. Das, and et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells Circulation 112 2005 720 726
28. S.B. Kapadia, and F.V. Chisari Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids Proc Natl Acad Sci U S A 102 2005 2561 2566
29. J. Ye, C. Wang, R. Sumpter Jr., M.S. Brown, J.L. Goldstein, and M. Gale Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation Proc Natl Acad Sci U S A 100 2003 15865 15870